In this issue:
Ibrutinib + rituximab for untreated mantle cell lymphoma
Radiation therapy utilisation for primary cutaneous T-cell lymphoma
Simplified frailty score for older patients with classical Hodgkin lymphoma
Tazemetostat for relapsed/refractory follicular lymphoma
Ten years of follow-up of ibrutinib for CLL/SLL
Epcoritamab or glofitamab for diffuse B-cell lymphoma
Tafasitamab + lenalidomide for diffuse large B-cell lymphoma: Spain
Tafasitamab + lenalidomide for diffuse large B-cell lymphoma: France
Risk prediction in diffuse large B-cell lymphoma
Ibrutinib and venetoclax in relapsed and refractory follicular lymphoma
Please login below to download this issue (PDF)